Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

Rhea-AI Summary

Ovid Therapeutics Inc. (NASDAQ: OVID) announced participation in a panel titled “Orphan Epilepsies” at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 12:50 p.m. ET in Boston, Massachusetts. A live webcast will be available on their website, with an archived replay following the event.

Ovid specializes in biopharmaceuticals aimed at treating epilepsies and brain disorders. Their development pipeline includes OV329 for treatment-resistant seizures and OV350 targeting the KCC2 transporter. They also hold a financial interest in soticlestat, currently in Phase 3 trials, which is being developed by Takeda.

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a panel titled “Orphan Epilepsies” at the Cowen 43^rd Annual Healthcare Conference in Boston, Massachusetts on March 6, 2023, at 12:50 p.m. ET.

A live webcast of the presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid’s pipeline of small molecule and genetic medicines candidates seek to meaningfully improve the lives of people and families affected by epilepsies. Ovid is developing OV329, a GABA-aminotransferase inhibitor that is in early clinical development for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. In addition, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Contacts
Investors and Media:
Ovid Therapeutics Inc.
Meg Alexander
917-943-6681
malexander@ovidrx.com

OR

Investors:
Argot Partners
Maeve Conneighton
212-596-7231
ovid@argotpartners.com

FAQ

What is the date and time of Ovid Therapeutics' presentation at the Cowen Conference?

Ovid Therapeutics will present on March 6, 2023, at 12:50 p.m. ET.

Where can I watch the Ovid Therapeutics presentation live?

The live webcast of the presentation can be accessed through the Events & Presentations section on Ovid's website.

What are the main products in Ovid Therapeutics' pipeline?

Ovid's pipeline includes OV329 for treatment-resistant seizures and OV350, a KCC2 transporter activator.

What is the significance of the Cowen 43rd Annual Healthcare Conference for Ovid Therapeutics?

The conference provides Ovid Therapeutics a platform to discuss advancements in treatments for orphan epilepsies.

What is soticlestat and its current status?

Soticlestat is a cholesterol 24-hydroxylase inhibitor in Phase 3 trials for Dravet and Lennox-Gastaut syndromes, developed by Takeda with Ovid holding financial interest.